BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé will retire in December, when he will be succeeded by Genentech CEO Alexander Hardy. The transition comes with BioMarin in the early stages of ...
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...
EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...
BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback